Glioblastoma Multiforme Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Glioblastoma Multiforme Market is segmented By Treatment type (Drugs (Temozolomide, Bevacizumab, Carmustine, Others), Immunotherapy, Electric field therapy, Others), By Type of molecule (Small molecules, Biologics), By Route of administration (Oral, Parenteral), By End-user (Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023- 2030.

Glioblastoma Multiforme Market Overview

The Global Glioblastoma Multiforme Market reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 4.5 billion by 2030. The global glioblastoma multiforme market is expected to exhibit a CAGR of 8.6% during the forecast period 2023-2030. The global glioblastoma multiforme (GBM) market is a dynamic and fast-evolving industry dedicated to diagnosing, treating and managing GBM, a highly aggressive brain tumor.

Advancements in imaging techniques, increasing focus on targeted therapies, personalized medicine approaches and adoption of innovative treatment modalities are some of the recent trends in the global glioblastoma multiforme market.

Furthermore, increasing incidence and prevalence and research and development activities are driving up the glioblastoma multiforme market size. Due to the expansion of research in these fields, the market is seeing an increase in demand from North American regions. With significant competitors like Pfizer, Innoviva, AbbVie Inc., Genentech, Amgen, Merck & Co., Inc. and others actively operating in the market.

Glioblastoma Multiforme Market Scope

To know more insights - Download Sample

Glioblastoma Multiforme Market Dynamics

Rising Incidence of Glioblastoma to Drive the Growth of the Glioblastoma Multiforme Market

The rising incidence of GBM cases around the world, which can be ascribed to a variety of risk factors such as ionizing radiation exposure, genetic predisposition and environmental variables, is pushing the demand for effective treatment alternatives and are likely to fuel global glioblastoma multiforme market size expansion throughout the forecast period.

For instance, according to the National Brain Tumor Society report of 2022, glioblastoma (GBM) is one of the most complex, fatal and resistant to treat malignancies. GBM constitutes 49.1% of all primary malignant brain tumors. Every year, more than 10,000 people in the United States are predicted to die from glioblastoma. The five-year survival rate for glioblastoma patients is approximately 6.8 percent, with an estimated average duration of survival of barely 8 months. Therefore, owing to the growing prevalence and fatalities due to GMB the market is expected to grow exponentially over the forecast period.

Extensive Research & Development Activities are Advancing the Growth of the Glioblastoma Multiforme Market

Extensive research and development activities in the field of GBM contribute to the discovery of new treatment options, improved patient outcomes and a transformed treatment landscape through advances in disease understanding, identification of therapeutic targets and development of novel approaches. These initiatives include targeted medicines, biomarker studies, clinical trials and cooperation between academic institutions, pharmaceutical corporations and research organizations.

For instance, the University of Florida is conducting a clinical trial in collaboration with the h Food and Drug Administration (FDA) for the Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) it consists of 40 participants. Currently, it is in phase 2 and the estimated completion date of the trial is June 2025. Therefore, owing to growing advancements in R&D activities will drive the glioblastoma multiforme market over the forecast period.

Side Effects Associated With Drugs Will Hamper the Growth of the Market

The cost of GBM therapies, like surgery, radiation therapy and chemotherapy, is frequently too expensive. This restricts accessibility, particularly in areas with insufficient healthcare coverage and low-income populations. The costs of these treatment options can be significant, necessitating multiple surgeries, hospital stays and follow-up care. 

Similarly, radiation therapy and chemotherapy regimens necessitate the purchase of costly equipment, drugs and supportive care. The high expense of GBM therapy presents difficulties for patients, particularly in areas with limited healthcare coverage and low-income populations. As a result, market growth will be limited over the projection period.

Glioblastoma Multiforme Market Segment Analysis

The global glioblastoma multiforme market is segmented based on treatment type, Molecule Type, route of administration, end user and region.

Owing to Effectiveness, the Temozolomide Segment Accounted for Approximately 31.7% of the Glioblastoma Multiforme Market Share

Temozolomide (TMZ) is a type of chemotherapy drug used to treat glioblastoma multiforme (GBM), a kind of brain cancer with a poor prognosis. TMZ is an orally given imidazotetrazine derivative that was initially designated as an orphan medication in 1998 for the treatment of recurrent malignant glioma. 

TMZ is a powerful radiosensitizer and an important component of chemoradiation therapy for patients with newly diagnosed glioblastoma and remains the backbone of therapy across all treatment settings. The combination of temozolomide with irradiation makes the tumor more responsive to irradiation and this combination of therapy is more successful than radiation alone.

Recently, there has been a significant surge in the usage of TMZ-based combination treatments, with multiple drugs currently being investigated in clinical studies. For instance, the University of Oklahoma is currently seeking patients for a clinical trial focused on treating newly diagnosed glioblastoma. The OKN-007 medication will be administered in combination with adjuvant concurrent radiation in the experiment. This combination medication is now in phase 2 clinical trials, with a completion deadline of June 30, 2025. 

Source: DataM Intelligence Analysis (2023)

Glioblastoma Multiforme Market Geographical Share

North America Accounted for Approximately 41.4% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for glioblastoma multiforme for treatment purposes in healthcare and the increase in prevalence, also the region has a well-established healthcare infrastructure and significant investments in research and development, North America has the chance of increasing its operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for glioblastoma multiforme. 

According to the American Society of Clinical Oncology (ASCO), in February 2022, approximately 25,050 adults (14,170 men and 10,880 women) in the United States would be diagnosed with primary malignant tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. 

In addition, approximately 4,170 children under the age of 15 were diagnosed with brain or CNS tumors in the United States this year. These characteristics demonstrate North America's dominant position in the global context.

Source: DataM Intelligence Analysis (2023)

Glioblastoma Multiforme Market Key players

The major global players in the glioblastoma multiforme market include Pfizer, Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., F. Hoffmann-Le Roche AG, Amneal Pharmaceuticals and Karyopharm Therapeutics, Inc., among others. 

Impact on Glioblastoma Multiforme Market

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has had a substantial impact on the global glioblastoma multiforme market. It has caused supply chain problems, resulting in GBM treatment shortages and price increases. Furthermore, the war has increased the costs of raw ingredients, shipping and insurance, making GBM treatments more expensive. 

Patient dislocation, hospital and clinic closures and a lack of medical supplies have all hampered access to care. These interruptions have had a severe impact on GBM patients, resulting in longer wait times, increased treatment costs and difficulty obtaining care. Furthermore, the war has hampered efforts to discover novel GBM treatments by restricting data access and communication among researchers.

By Treatment Type

• Drugs 
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Others
• Immunotherapy 
• Targeted Therapy
• Others

By Molecule Type

• Small Molecules 
• Biologics 

By Route of Administration

• Oral
• Parenteral

By End User

• Hospitals and Clinics 
• Cancer Treatment Centers
• Others 

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On June 3, 2023, Chimeric Therapeutics announced the start of a new Phase IB clinical trial of CHM 1101 (CLXT CAR T) cell therapy for the treatment of individuals with recurrent or progressive glioblastoma multiforme (GBM). The trial will look at the safety and efficacy of CHM 1101 in people who have the deadliest type of primary brain cancer.
• On March 8, 2023, according to a press release from the drug maker, Genenta Science, the FDA granted orphan drug status to the cell therapy Temferon for the treatment of patients with glioblastoma multiforme (GBM).  
• On January 13, 2022,  ITM Isotope Technologies Munich SE (ITM), a renowned radiopharmaceutical biotech company and Helmholtz Munich (Helmholtz Zentrum München) announced a collaboration agreement for the clinical development of a radiopharmaceutical therapeutic candidate for the glioblastoma treatment, a malignant brain tumor.

Why Purchase the Report?

• To visualize the global glioblastoma multiforme market segmentation based on treatment type, Molecule Type, route of administration, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of glioblastoma multiforme market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global glioblastoma multiforme market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies